BGNE
BeiGene, Ltd.
179.64
USD
This page is just a preview of the data found in TrendSpider’s full version
BeiGene, Ltd. stock is down -10.27% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 2 CALLs, 8 PUTs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 09 Nov 17:49 | 17 Nov, 2023 | 150.00 | 8 | ||
| 15 Nov 16:20 | 17 May, 2024 | 185.00 | 0 | ||
| 06 Dec 16:09 | 17 May, 2024 | 185.00 | 15 | ||
| 06 Dec 16:12 | 17 May, 2024 | 190.00 | 2 | ||
| 06 Dec 16:40 | 17 May, 2024 | 250.00 | 0 | ||
| 06 Dec 16:41 | 17 May, 2024 | 250.00 | 0 | ||
| 06 Dec 17:36 | 17 May, 2024 | 250.00 | 0 | ||
| 06 Dec 17:47 | 17 May, 2024 | 270.00 | 0 | ||
| 06 Dec 18:45 | 17 May, 2024 | 280.00 | 0 | ||
| 06 Dec 18:46 | 17 May, 2024 | 280.00 | 0 |
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma. Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC)
